EcoDrugPlus

Kit Proto-Oncogene, Receptor Tyrosine Kinase B

Ensembl ID : ENSEEEG00000007995
Gene Symbol: KITB
4 Cross references
208 Possible Orthologues:

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSEEEG00000021950
Gene Symbol: LYN
4 Cross references
196 Possible Orthologues:

Malt1 Paracaspase

Ensembl ID : ENSEEEG00000022380
Gene Symbol: MALT1
2 Cross references
198 Possible Orthologues:

Mapk Activated Protein Kinase 2a

Ensembl ID : ENSEEEG00000017964
Gene Symbol: MAPKAPK2A
4 Cross references
145 Possible Orthologues:

Mapk Activated Protein Kinase 2b

Ensembl ID : ENSEEEG00000002006
Gene Symbol: MAPKAPK2B
4 Cross references
170 Possible Orthologues:

Mapk Activated Protein Kinase 5

Ensembl ID : ENSEEEG00000022058
Gene Symbol: MAPKAPK5
4 Cross references
179 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2a

Ensembl ID : ENSEEEG00000020124
Gene Symbol: MKNK2A
4 Cross references
156 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2b

Ensembl ID : ENSEEEG00000017560
Gene Symbol: MKNK2B
4 Cross references
208 Possible Orthologues:

Mcl1 Apoptosis Regulator, Bcl2 Family Member A

Ensembl ID : ENSEEEG00000008733
Gene Symbol: MCL1A
4 Cross references
150 Possible Orthologues:

Mcl1 Apoptosis Regulator, Bcl2 Family Member B

Ensembl ID : ENSEEEG00000021442
Gene Symbol: MCL1B
4 Cross references
229 Possible Orthologues:

Mdm2 Proto-Oncogene

Ensembl ID : ENSEEEG00000024537
Gene Symbol: MDM2
4 Cross references
285 Possible Orthologues:

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSEEEG00000000572
Gene Symbol: MET
2 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).